Evidence map›Paper›PMID 35633535›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

Antiproliferative Activities of Lipophililic Fluoroquinolones- Based Scaffold Against a Panel of Solid and Liquid Cancer Cell Lines.

Esraa Qashou, Yusuf Al-Hiari, Violet Kasabri, Rabab AlBashiti, Sundus AlAlawi, Ahmad Telfah, Amani AlHadid

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Selected Statins as Dual Antiproliferative-Antiinflammatory Compounds.Asian Pacific journal of cancer prevention : APJCP · 2022
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Esraa QashouSchool of Pharmacy, University of Jordan, Amman 11942, Queen Rania Street, Jordan.
Yusuf Al-HiariSchool of Pharmacy, University of Jordan, Amman 11942, Queen Rania Street, Jordan.
Violet KasabriSchool of Pharmacy, University of Jordan, Amman 11942, Queen Rania Street, Jordan.ORCID 0000-0003-1927-0193
Rabab AlBashitiSchool of Pharmacy, University of Jordan, Amman 11942, Queen Rania Street, Jordan.
Sundus AlAlawiSchool of Pharmacy, University of Jordan, Amman 11942, Queen Rania Street, Jordan.
Ahmad TelfahLeibniz Institut für analytische Wissenschaften - ISAS e.V. Bunsen-Kirchhoff-Str.1144139 Dortmund, Germany.
Amani AlHadidSchool of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.
University of Jordan · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIn this work, 9 lipophilic-acid chelating FQs (fluoroquinolones) comprising chelating groups  have been prepared, characterized and screened for in vitro cytotoxicity, radical scavenging and antiinflammation propensities.

methodsUsing sulforhodamine B colorimetric bioassay vs. cisplatin; FQs-inflicted reductions' of viability against breast T47D and MCF7, Pancreatic PANC-1, colorectal HT29, HCT116, SW620, CACO2, SW480 and Leukaemia K562 cancer cell lines were examined in quadruplicates/dose/cell line. Parameters including potency, toxicity, and selectivity (potency/toxicity) have been reported along with DPPH- and NO- radicals' scavenging capacities -as their molecular action mechanism- in comparison to ascorbic acid and indomethacin respectively. Using Griess assay in Lipopolysaccharide (LPS) prompted RAW264.7 macrophages; mitigation of inflammation was investigated.

resultsnitroFQ 3b, unlike the rest of FQs in PANC1 and MCF7 cells, exhibited remarkably superior NO-radical scavenging/antiinflammation capacity to indomethacin with respective antiproliferative IC50 values (<50µM) 49 vs. cisplatin's 122 and 6 vs. cisplatin's 28 (p<0.01-0.001; n=4). Reduced FQ 4b of significantly dual DPPH-NO scavenging propensities exerted exceptionally substantial micromolar antiproliferation in colorectal cancer cells with respective antiproliferative IC50 values (<50µM) of HCT116 0.84< HT29 1.6<PANC1 5.7<SW620 9.2 vs. cisplatins', (p<0.01-0.001; n=4). FQ 5a of superb NO radical reduction effect had antiproliferative IC50 value (<50µM) of 37.6 in PANC1 cells. In breast cancer T47D the ascending order of pronounced nano-micromolar antiproliferative IC50 values (<50µM) was 4d<3d<4a<4b<3b (0.009<0.59<10<15<41 vs. cisplatins', p<0.01-0.001; n=4). Both 4d and 4b displayed both DPPH-NO radicals reduction -related cytotoxicities. NO radical scavengers 3d and 3b as well as DPPH radical scavenger 4a exerted highly appreciably relevant antineoplastic affinities.

conclusionAcidic groups and C8-C7 ethylene diamine Chelation Bridge along with bulky dual halogenations can be substantially associated with molecular action mechanisms of FQs cytotoxicities, antioxidative and antiinflammation effects, collectively.

Indexed as

Antineoplastic AgentsNeoplasmsAnti-Inflammatory AgentsCaco-2 CellsCisplatinFluoroquinolonesHumansIndomethacinAnti-Inflammatory AgentsAntineoplastic AgentsCisplatinFluoroquinolonesIndomethacinAntiinflammation and antiCancerCisplatinFluoroquinolonesNO-radical scavengingSulphorodhamine B

Identifiers

PMID35633535
PMCPMC9587871
OpenAlexW4281907650

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.